Collaboration drives innovation! We’re actively seeking partners in cell therapy and regenerative medicine to explore how our encapsulation platform can enhance therapeutic delivery, improve cell retention, and optimize treatment outcomes. Whether you're looking to increase persistence, improve yield, or streamline scalability, our hydrogel encapsulation technology is designed to help. Let’s work together to push the boundaries of next-generation therapies. ?? Interested in partnering? Let’s connect! DM us or email [email protected].
关于我们
- 网站
-
https://www.likarda.com
Likarda的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Kansas City,Missouri
- 类型
- 私人持股
- 创立
- 2012
- 领域
- Cell-based Therapies、Cell Therapy、Encapsulation、Microencapsulation、Cell-based Assay Development、Biotechnology和Hydrogels
地点
-
主要
10330 Hickman Mills Dr
US,Missouri,Kansas City
Likarda员工
动态
-
How do you ensure cell therapies reach their full potential? It starts with delivery. In this video, Dr. Francis Karanu discusses a Likarda diabetes treatment—one made possible by Likarda’s Core Shell Spherification (CSS) technology. Our patented encapsulation platform enhances therapeutic delivery, improves retention, and optimizes treatment outcomes. Best of all? It’s customizable to fit your therapy’s unique needs. ?? Watch the video to see how CSS is unlocking new opportunities for cell therapy! Then let’s connect and explore how this could work for you!
-
Did you know March is National Colorectal Cancer Awareness Month? Colorectal cancer remains one of the most diagnosed cancers worldwide. It’s the leading cause of cancer-related deaths in men and the second in women under 50, highlighting the urgent need for more effective treatment strategies—including targeted drug delivery and advanced cell therapies. At Likarda, we’re exploring how hydrogel encapsulation can push the boundaries of treatment innovation by: ?? Enhancing Targeted Drug Delivery – Our customized hydrogel technology improves retention, precision, and immune evasion of therapeutic cells in the tumor microenvironment, potentially increasing treatment effectiveness. ?? Optimizing Cell Therapy for CRC – Encapsulation protects and sustains cell-based therapies, ensuring a more prolonged immune response against tumors while reducing off-target effects. We’d love to hear from those working in CRC treatments—What breakthroughs do you see on the horizon for colorectal cancer treatment? What are the biggest challenges in optimizing localized drug release? ?? Drop your insights in the comments or reach out. We’re always looking to collaborate with experts shaping the future of cancer treatment.
-
-
Struggling with poor cell retention or inconsistent dosing in your therapy? You’re not alone. Scaling up cell therapies presents significant challenges, but our advanced encapsulation technology is designed to overcome key hurdles, enhancing stability, delivery, and therapeutic efficacy. By enabling controlled, scalable delivery, we help improve: ? Persistence – Keeping therapeutic cells where they’re needed most ? Yield – Maximizing efficiency and reducing waste ? Function – Enhancing therapeutic impact for better patient outcome
此处无法显示此内容
在领英 APP 中访问此内容等
-
Bringing cell therapies from the lab to real-world application isn’t just about discovery—it’s about overcoming barriers to clinical success. Scaling these therapies requires optimizing delivery without sacrificing quality, efficacy, or consistency. At Likarda, we’re leading the way in hydrogel encapsulation technology, refining solutions for both in vitro and in vivo applications. By enhancing yield, reproducibility, and therapeutic impact, we help ensure that cell-based therapies can be delivered at scale—efficiently and effectively. Let’s explore how we can optimize your therapy. Drop a comment, DM, or email to [email protected] to discuss a FREE consultation with our team. #HealthcareInnovation #DrugDevelopment #FutureofMedicine
-
?? BIG NEWS! ?? What if a single dose of therapy could last months instead of days? That’s exactly what we’re working on at Likarda—and we’ve just received a major grant to bring this innovation to life! Many infectious diseases require frequent dosing, creating treatment challenges and poor adherence. Our Core-Shell Spherification? platform encapsulates therapeutic cells in a tunable hydrogel system, protecting them from immune clearance while enabling the controlled release of antibodies over an extended period of several months to a year. Why This Changes Everything: ?? Immune Protection – Shields cells for extended therapeutic impact. ?? Temperature-Stable Hydrogel – Built for durability and controlled release. ?? Expanding What’s Possible – Bringing scalable, long-term cell-based therapies closer to reality. ?? Read the full press release here: https://lnkd.in/g76dYYEm And this is just the beginning! ?? Hit ‘Follow’ to stay updated as Likarda continues to push the boundaries of what’s possible in biotech and global health. #HealthcareInnovation #CellTherapy #InfectiousDisease #DrugDelivery
-
-
?? Exciting News! ?? Likarda and our customer VitalTE are featured in the latest issue of European Pharmaceutical Manufacturer, discussing how hydrogels are transforming hormone delivery! ?? Our encapsulated hydrogel technology enables slow, controlled hormone release over the course of weeks, providing a more effective and patient-friendly injectable alternative to traditional pellet-based delivery. Preclinical studies indicate that our hydrogel microbeads achieve a similar release rate to pellet delivery, but with one key advantage—no need for an in-office insertion procedure! ?? Want to learn more? Check out the article and explore how Likarda is shaping the future of hormone delivery and drug release technologies. #DrugDelivery #Hydrogels #PharmaceuticalInnovation #HormoneTherapy #Biotech #Likarda #VitalTE #European Pharmaceutical Manufacturer
?? The latest issue of European Pharmaceutical Manufacturer is out NOW! ?? Read the full magazine here: https://lnkd.in/dJwHUiQj Sonia Schwantes, MBA, NewAge Industries, Inc. shares how the company is delivering value and sustainability. Stevanato Group delves into the one-stop shop for even the most challenging monoclonal antibodies. Aimee Hodge, PCI Pharma Services discusses PPQ pitfalls and how to avoid them. Deepa Pandey, Towards Packaging highlights the importance of flexible pouches in the pharma industry. Marcelo Cruz, Tjoapack explores the secondary innovations poised to revolutionise the patient centricity of prefilled syringes. Paul Hardman, Broughton looks into ways to reduce greenhouse gases in pharma. Danny Jones, ZwickRoell UK & Ireland highlights advances in parental drug delivery products and testing methods. Dr. Charles Virden, VitalTE LifeSciences Inc and Lisa Stehno-Bittel, Likarda discuss a new approach to HRT. Jeff Serle, Germfree demonstrates how multimodal and modular cleanrooms can satisfy all requirements. Beverley Wise, Webfleet, Bridgestone EMEA explores how fleet tech is reshaping the pharma supply chain. Stephen Cawley, Biocair shares the challenges and innovations in sustainability for the life sciences supply chain. Caroline Suard, Tower Cold Chain discusses the critical role of thermal packaging solutions in logistics. Kevin Lynch, Schneider Electric explains how the sector can leverage digital technologies to streamline the technology learning curve. Harvey Branton, eXmoor Pharma shares insights into early process development, exploring common misconceptions that could impact long-term manufacturing success for ATMP developers. Ray Baldwin, Watson-Marlow Fluid Technology Solutions explains how all single-use is not created equal and how you can tell the difference. Lars Petersen, FUJIFILM Diosynth Biotechnologies shares the latest updates on the ongoing expansion at the Hiller?d facilities. #packaging #biopharma #manufacturing #cleanrooms
-
-
Big solutions start with bold ideas! We’re excited to announce that Likarda has been selected to present at the BioTools Innovator East Coast Pitch Event tomorrow in Boston! Our Founder & President, Dr. Lisa Stehno-Bittel, will take the stage to showcase how Likarda's breakthrough cell therapy delivery technology is transforming the future of healthcare. This event brings together industry leaders, investors, and top innovators in life science tools and diagnostics—all focused on pushing the boundaries of biotech. We’re honored to be part of the conversation and can’t wait to share how our next-gen encapsulation platform is revolutionizing cell therapy. If you’re attending, let’s connect! Looking forward to an exciting day of innovation and collaboration. #BTIRoadTour2025 #CellTherapy #BiotechInnovation #StartupPitch
-
-
At Likarda, we don’t just talk about women in leadership—we live it. With a female President, CEO and CCO, we’re proof that when women lead, industries evolve, innovation accelerates, and meaningful change happens. As the world celebrates #InternationalWomensDay on March 8th, we honor the women making strides in science, medicine, and beyond—those who ask the tough questions, challenge the status quo, and push the boundaries of what’s possible. To every woman forging a path in biotech, healthcare, and STEM—keep leading, keep inspiring, and keep changing the world. We see you. We celebrate you. #WomenInSTEM #WomenInScience
-
-
What’s next for biopharma in 2025? In the latest installment of "Scrip Asks...", over 140 biopharma leaders—including Likarda CEO Stella K. Vnook—shared their insights on the biggest therapeutic advancements shaping the year ahead. From breakthroughs in oncology and immunology to game-changing innovations in cardiometabolism and neurology, the industry is set for a transformative year. ?? Read the full article, written by Eleanor Malone, here: https://bit.ly/3F281lk ?? What do you think will be the most impactful advancement in biopharma this year? Share your thoughts in the comments! #pharmainnovation #biotech Citeline
-